Endometriosis, inflammation, and GLP-1 drugs: Promise, placebo, or a path forward?

Editorial note: Welcome to our Expert Advice column. To ensure you get the most accurate medical information, the following piece by Virginia Elizabeth Mclean, MD, FACOG, and Pankaj Singhal, MD, MS, MHCM, FACOG, of New York Gynecology Surgery and Endometriosis is presented exactly as they wrote it (i.e., it’s unedited).

Over the past year, a growing number of my patients with endometriosis have reported something unexpected: fewer inflammatory flares, less bloating, and, in some cases, meaningful pain relief after starting GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) for metabolic indications.

These observations are anecdotal and highly variable—but they are not scientifically trivial. They raise an important question for clinicians and researchers alike: Are GLP-1 medications merely coincidentally improving symptoms, or are they intersecting with core biological pathways that drive endometriosis?

Why The Link Between GLP-1 Drugs and Endometriosis Makes Biological Sense

Endometriosis is not a localized pelvic disorder. It is a systemic inflammatory disease shaped by immune dysregulation, estrogen signaling, metabolic stress, and central nervous system pain amplification. It also involves the gut–brain–immune axis—a bidirectional network linking intestinal function, neuroinflammation, and chronic pain.

GLP-1 receptor agonists act on the same systems. In other conditions, they have been shown to:

• Reduce inflammatory cytokines
• Lower oxidative stress
• Improve insulin resistance
• Alter gut motility and gut-brain signaling
• Modulate central pain pathways
• Influence reproductive hormone environments

This overlap alone makes the patient reports biologically plausible rather than dismissible.

The Most Compelling Evidence Linking GLP-1s and Endometriosis So Far

The most intriguing data come from studies of endometrial hyperplasia and endometrial cancer.

In laboratory models, GLP-1 receptor agonists were found to increase progesterone receptor expression in endometrial cells. When combined with progestins—already a mainstay of hormonal therapy for both hyperplasia and endometriosis—the response was stronger than with progestins alone. In cancer models, this synergy led to increased tumor cell apoptosis.

Why this matters for endometriosis: Progesterone resistance is a known biological problem in many patients with endometriosis. If GLP-1 drugs truly enhance progesterone receptor responsiveness, they could one day serve as adjuncts to hormonal therapy—not as replacements, but as biological amplifiers of treatment effect.

This is not proven. But it is the first genuine molecular “signal” linking GLP-1 pathways to endometriosis biology.

Why Some Patients Experience Endometriosis Symptom Relief on Ozempic and Wegovy

The symptom improvements reported by some patients are most likely indirect:

• Reduced visceral fat → lower peripheral estrogen production
• Improved insulin sensitivity → less growth-factor signaling
• Decreased systemic inflammation → less pelvic neuroinflammation
• CNS effects → altered pain perception and stress response
• Gut-brain modulation → reduced bloating and visceral hypersensitivity
• Upregulation of progesterone receptors

Why GLP-1s Aren’t an Approved Endometriosis Treatment Yet

At present, GLP-1 receptor agonists are not approved for the treatment of endometriosis. Key limitations and risks include:

• Not covered by major insurance plans and expensive to pay cash
• Gastrointestinal side effects that may worsen “endo belly.”
• Delayed gastric emptying that can impair absorption of oral progestins and contraceptives
• Mandatory discontinuation before pregnancy due to incomplete fetal safety data
• Potential bone density loss with rapid weight reduction
• Highly variable mood and neuropsychiatric effects

The Bottom Line

GLP-1 receptor agonists are currently used only for standard medical indications such as type 2 diabetes, obesity, insulin resistance, or cardiometabolic disease—always within a care plan that accounts for reproductive goals and concurrent hormonal therapy.

That said, the emerging biology is not trivial. We believe that these drugs decrease inflammation, metabolic signaling, neuroendocrine regulation, and gut–brain communication, and augment progesterone receptor expression—systems that sit at the core of endometriosis pathophysiology and can help treat endometriosis.

References

1. Mehdi SF, et al. Glucagon-like peptide-1 as a multi-faceted modulator of inflammatory pathways and oxidative stress. Biochem Pharmacol. 2023;215:115770.
View Study →

2. Alharbi SH, et al. Anti-inflammatory role of glucagon-like peptide-1 receptor agonists: mechanisms and therapeutic implications. Front Pharmacol. 2024;15:1345672.
View Study →

3. Sola-Leyva A, et al. The hidden impact of GLP-1 receptor agonists on endometrial function and female fertility. Acta Obstet Gynecol Scand. 2024;103(11):2134-2144.
View Study →

4. Hagemann AR, et al. Enhancing progestin therapy with a glucagon-like peptide-1 agonist for conservative management of endometrial cancer. Cancers (Basel). 2025;17(4):598.
View Study →

5. Krasnyi AM, et al. Levels of ghrelin, glucagon, visfatin and GLP-1 are altered in the peritoneal fluid of women with endometriosis. Biomolecules. 2022;12(10):1443.
View Study →

6. He Y, et al. Advances in GLP-1 receptor agonists for pain treatment: neuroprotective and metabolic regulatory mechanisms. J Headache Pain. 2025;26:41.
View Study →